0001179110-13-000807.txt : 20130111 0001179110-13-000807.hdr.sgml : 20130111 20130111203110 ACCESSION NUMBER: 0001179110-13-000807 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130109 FILED AS OF DATE: 20130111 DATE AS OF CHANGE: 20130111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WOOD JULIANNA R CENTRAL INDEX KEY: 0001282660 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28298 FILM NUMBER: 13526406 MAIL ADDRESS: STREET 1: 3031 RESEARCH DR STREET 2: BLDG A CITY: RICHMOND STATE: CA ZIP: 84806 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012140 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943154463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-0000 MAIL ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgar.xml FORM 4 - X0306 4 2013-01-09 0 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001282660 WOOD JULIANNA R C/O ONYX PHARMACEUTICALS, INC. 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 VP, Public Affairs Common Stock 2013-01-09 4 M 0 1027 28.55 A 19246 D Common Stock 2013-01-09 4 M 0 511 30.28 A 19757 D Common Stock 2013-01-09 4 M 0 3646 35.18 A 23403 D Common Stock 2013-01-09 4 M 0 1438 37.68 A 24841 D Common Stock 2013-01-09 4 S 0 6622 85.00 D 18219 D Common Stock 200 I Children's Trust Stock Option (Right to Buy) 28.55 2013-01-09 4 M 0 1027 0.00 D 2019-03-31 Common Stock 1027 3213 D Stock Option (Right to Buy) 30.28 2013-01-09 4 M 0 511 0.00 D 2020-03-31 Common Stock 511 8676 D Stock Option (Right to Buy) 35.18 2013-01-09 4 M 0 3646 0.00 D 2021-03-31 Common Stock 3646 13854 D Stock Option (Right to Buy) 37.68 2013-01-09 4 M 0 1438 0.00 D 2022-03-29 Common Stock 1438 21562 D Shares sold pursuant to a 10b5-1 plan. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months. /s/ Warren DeSouza, Attorney-in-fact 2013-01-11